insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

TMBR · Timber Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$2.47M$2.37M-$1.79M$3.89M$1.52M-$1.97M$1.80M$1.02M
SG&A$1.37M$1.63M-$1.34M$1.51M$1.70M-$1.30M$1.56M$456.8K
Total Operating Expenses$4.00M$4.00M-$3.13M$9.40M$3.22M-$3.27M$3.36M$2.66M
D&A-$1.3K---$787----
Operating Income($4.00M)($4.00M)-($3.13M)($9.40M)($3.14M)-($3.00M)($2.97M)($2.64M)
Interest Expense----------
Income Tax----------
Net Income($4.06M)($4.06M)-($3.19M)($9.50M)($3.07M)-($3.01M)($2.97M)($3.52M)
EPS - Basic($1.32)($1.32)-($1.52)($0.15)($0.05)-($0.08)--
EPS - Diluted---($1.52)($0.08)($0.05)-($0.08)--

Balance Sheet

Line itemQ2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Cash & Equivalents$2.52M$5.18M$9.08M$11.22M$8.27M$13.86M$16.81M$3.36M$6.13M$8.50M
Accounts Receivable----------
Inventory----------
Accounts Payable$1.63M$1.01M$1.35M$953.5K$420.4K$818.8K$953.3K$1.04M$1.39M$523.8K
Current Assets$2.79M$5.50M$9.81M$12.24M$9.28M$14.07M$17.12M$3.70M$6.76M$8.79M
Total Assets$3.33M$6.28M$10.28M$12.79M$9.91M$14.78M$17.90M$4.55M$7.69M$9.77M
Current Liabilities$5.62M$4.67M$5.04M$5.00M$6.57M$3.91M$4.19M$2.02M$2.25M$1.33M
Long-term Debt----------
Total Liabilities$5.95M$4.97M$5.04M$5.16M$8.56M$4.22M$4.63M$2.59M$2.90M$2.07M
Stockholders' Equity($2.62M)$1.31M$5.23M$7.63M$1.35M$10.56M$13.27M($51.0K)$2.80M$5.76M
Retained Earnings($56.39M)($52.33M)($48.26M)($44.64M)($41.45M)($31.96M)($28.88M)($26.09M)($23.09M)($20.12M)

Cash Flow

Line itemQ2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Operating Cash Flow-($3.90M)---($2.94M)---($1.61M)
Investing Cash Flow-($2.0K)---($3.5K)---($1.25M)
Financing Cash Flow-$0-------$3.70M
CapEx-$2.0K---$3.5K----
Free Cash Flow-($3.90M)---($2.95M)----

Ratios

MetricQ2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income-0.96---0.96----
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-122.2%-64.7%--24.9%-95.8%-20.8%--66.0%-38.6%-36.0%
Return on equity155.0%-309.8%--41.8%-703.6%-29.1%-5891.8%-105.8%-61.1%
Return on invested capital----------
Liquidity
Current ratio0.501.181.952.451.413.604.081.833.016.59
Quick ratio0.501.181.952.451.413.604.081.833.016.59
Cash ratio0.451.111.802.241.263.554.011.672.726.37
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier-1.274.791.961.687.341.401.35-89.252.741.70
Liabilities / Assets1.790.790.490.400.860.290.260.570.380.21
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)57.5%-27.5%--4.1%-216.9%-19.0%--420.3%-1459.4%-
Net income growth (YoY)57.2%-32.1%--6.1%-220.1%12.7%--420.5%80.5%-
EPS growth (YoY)----1800.0%------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)--32.4%--------
FCF CAGR (5y)----------
Book value growth (YoY)--87.6%-60.5%--51.9%83.4%74.4%---

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Timber Pharmaceuticals against the 5 most active filers in the same SIC group.